Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression.

[1]  Michael Maes.  Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[2]  T. Hoshuyama,et al.  Plasma levels of brain‐derived neurotrophic factor and interleukin‐6 in patients with dysthymic disorder: comparison with age‐ and sex‐matched major depressed patients and healthy controls , 2010, Human psychopharmacology.

[3]  O. Forlenza,et al.  Increased soluble TNF receptor 2 in antidepressant-free patients with late-life depression. , 2010, Journal of psychiatric research.

[4]  J. Herman,et al.  Stress activation of IL-6 neurons in the hypothalamus. , 2010, American journal of physiology. Regulatory, integrative and comparative physiology.

[5]  N. Herrmann,et al.  A Meta-Analysis of Cytokines in Major Depression , 2010, Biological Psychiatry.

[6]  O. Forlenza,et al.  Interleukin-1beta serum levels is increased in antidepressant-free elderly depressed patients. , 2010, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[7]  E. Tan,et al.  Alcohol and Aldehyde Dehydrogenase Polymorphisms in Chinese and Indian Populations , 2010, Substance use & misuse.

[8]  O. Wolkowitz,et al.  Low serum IL-10 concentrations and loss of regulatory association between IL-6 and IL-10 in adults with major depression. , 2009, Journal of psychiatric research.

[9]  J. Suls,et al.  Associations of Depression With C-Reactive Protein, IL-1, and IL-6: A Meta-Analysis , 2009, Psychosomatic medicine.

[10]  J. Cavaillon,et al.  Compensatory anti-inflammatory response syndrome , 2008, Thrombosis and Haemostasis.

[11]  M. E. Hernández,et al.  Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder , 2008, European Neuropsychopharmacology.

[12]  Stafford L. Lightman,et al.  The HPA axis in major depression: classical theories and new developments , 2008, Trends in Neurosciences.

[13]  M. H. Pollack,et al.  A detailed examination of cytokine abnormalities in Major Depressive Disorder , 2008, European Neuropsychopharmacology.

[14]  E. Maron,et al.  Pro-inflammatory cytokines and treatment response to escitaloprsam in major depressive disorder , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[15]  E. Shevach,et al.  Pro- and Anti-Inflammatory Cytokine Balance in Major Depression: Effect of Sertraline Therapy , 2008, Clinical & developmental immunology.

[16]  Chien-Te Lee,et al.  T‐helper 1/T‐helper 2 cytokine imbalance and clinical phenotypes of acute‐phase major depression , 2007, Psychiatry and clinical neurosciences.

[17]  P. Scully,et al.  Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. , 2007, Journal of psychiatric research.

[18]  G. Xie,et al.  Levels of Serum Interleukin (IL)-6, IL-1β, Tumour Necrosis Factor-α and Leptin and Their Correlation in Depression , 2007 .

[19]  S. Matsuda,et al.  Microglia‐derived interleukin‐6 and leukaemia inhibitory factor promote astrocytic differentiation of neural stem/progenitor cells , 2007, The European journal of neuroscience.

[20]  A. Siracusano,et al.  Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy. , 2006, The Journal of clinical psychiatry.

[21]  Henrik Ahlenius,et al.  Tumor Necrosis Factor Receptor 1 Is a Negative Regulator of Progenitor Proliferation in Adult Hippocampal Neurogenesis , 2006, The Journal of Neuroscience.

[22]  R. Duman,et al.  TNFα Signaling in Depression and Anxiety: Behavioral Consequences of Individual Receptor Targeting , 2006, Biological Psychiatry.

[23]  M. Irwin,et al.  Dissociation of inflammatory markers and natural killer cell activity in major depressive disorder , 2006, Brain, Behavior, and Immunity.

[24]  M. E. Hernández,et al.  Th2 cytokine response in Major Depressive Disorder patients before treatment , 2006, Journal of Neuroimmunology.

[25]  E. Göka,et al.  IL‐6 levels decrease with SSRI treatment in patients with major depression , 2005, Human psychopharmacology.

[26]  H. Steinbusch,et al.  Th1, Th2, and Th3 cytokine alterations in major depression. , 2005, Journal of affective disorders.

[27]  B. Grant,et al.  Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. , 2005, Archives of general psychiatry.

[28]  S. Tzeng,et al.  Tumor necrosis factor-α and interleukin-18 modulate neuronal cell fate in embryonic neural progenitor culture , 2005, Brain Research.

[29]  E. Cacci,et al.  Microglia‐derived tumor necrosis factor‐α exaggerates death of newborn hippocampal progenitor cells in vitro , 2005, Journal of neuroscience research.

[30]  M. Irwin,et al.  Inflammatory Markers and Sleep Disturbance in Major Depression , 2005, Psychosomatic medicine.

[31]  William A Banks,et al.  Blood-brain barrier transport of cytokines: a mechanism for neuropathology. , 2005, Current pharmaceutical design.

[32]  A. Simopoulos.  Genetic variation: nutritional implications. , 2004, World review of nutrition and dietetics.

[33]  Maristela Monteiro,et al.  The Global Distribution of Average Volume of Alcohol Consumption and Patterns of Drinking , 2003, European Addiction Research.

[34]  O. Çalıyurt,et al.  Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder , 2003, Psychopharmacology.

[35]  O. Nishikaze,et al.  Comparison of Immunological and Endocrinological Markers Associated with Major Depression , 2003, The Journal of international medical research.

[36]  N. Sartorius.  The economic and social burden of depression. , 2001, The Journal of clinical psychiatry.

[37]  E. Bosmans,et al.  Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis , 2001, European Neuropsychopharmacology.

[38]  S. Yamawaki,et al.  Plasma Concentrations of Interleukin-1β, Interleukin-6, Soluble Interleukin-2 Receptor and Tumor Necrosis Factor α of Depressed Patients in Japan , 2001, Neuropsychobiology.

[39]  E. Bosmans,et al.  Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission. , 2000, Polish journal of pharmacology.

[40]  F. Brambilla,et al.  Blood levels of cytokines in elderly patients with major depressive disorder , 1998, Acta psychiatrica Scandinavica.

[41]  E. Bosmans,et al.  Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. , 1997, Cytokine.

[42]  M. Berk,et al.  Acute phase proteins in major depression. , 1997, Journal of psychosomatic research.

[43]  E. Bosmans,et al.  Indicators of immune activation in major depression , 1996, Psychiatry Research.

[44]  V. Rettori,et al.  Mechanism of Action of Cytokines to Induce the Pattern of Pituitary Hormone Secretion in Infection a , 1995, Annals of the New York Academy of Sciences.

[45]  H. Meltzer,et al.  Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. , 1995, Journal of affective disorders.

[46]  G. Chrousos,et al.  The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. , 1995, The New England journal of medicine.

[47]  H. Meltzer,et al.  Plasma-soluble interleukin-2 and transferrin receptor in schizoprenia and major depression , 1995, European Archives of Psychiatry and Clinical Neuroscience.

[48]  H. Meltzer,et al.  Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: Further evidence for an immune response , 1994, Psychiatry Research.

[49]  B. Leonard,et al.  Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. , 1994, Journal of affective disorders.

[50]  P. Black.  Immune system-central nervous system interactions: effect and immunomodulatory consequences of immune system mediators on the brain , 1994, Antimicrobial Agents and Chemotherapy.

[51]  H. Meltzer,et al.  Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression? , 1993, The American journal of psychiatry.

[52]  M. Jadoul,et al.  Direct stimulation of cytokines (IL-1β, TNF-α, IL-6, IL-2, IFN-γ and GM-CSF) in whole blood: II. Application to rheumatoid arthritis and osteoarthritis , 1992 .

[53]  P. Cosyns,et al.  Higher alpha 1-antitrypsin, haptoglobin, ceruloplasmin and lower retinol binding protein plasma levels during depression: further evidence for the existence of an inflammatory response during that illness. , 1992, Journal of affective disorders.

[54]  E. Bosmans,et al.  Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining , 1992, Psychological Medicine.

[55]  E. Bosmans,et al.  Depression‐related disturbances in mitogen‐induced lymphocyte responses and interleukin‐1β and soluble interleukin‐2 receptor production , 1991, Acta psychiatrica Scandinavica.

[56]  A. Khoruts,et al.  Circulating tumor necrosis factor, interleukin‐1 and interleukin‐6 concentrations in chronic alcoholic patients , 1991, Hepatology.

[57]  E. Bosmans,et al.  Antiphospholipid, antinuclear, Epstein-Barr and cytomegalovirus antibodies, and soluble interleukin-2 receptors in depressive patients. , 1991, Journal of affective disorders.

[58]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[59]  R. Karmali,et al.  Elevated levels of prostaglandin E2 and thromboxane B2 in depression. , 1983, Prostaglandins, leukotrienes, and medicine.

[60]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[61]  E. Maron,et al.  Soluble interleukin-2 receptor and tumor necrosis factor levels in depressed patients in Estonia. , 2009, Medicina.

[62]  E. Maron,et al.  Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. , 2008, Progress in neuro-psychopharmacology & biological psychiatry.

[63]  R. Dantzer,et al.  From inflammation to sickness and depression: when the immune system subjugates the brain , 2008, Nature Reviews Neuroscience.

[64]  G. Xie,et al.  Levels of serum interleukin (IL)-6, IL-1beta, tumour necrosis factor-alpha and leptin and their correlation in depression. , 2007, The Australian and New Zealand journal of psychiatry.

[65]  M. Maj,et al.  Interleukin-1beta and tumor necrosis factor-alpha in children with major depressive disorder or dysthymia. , 2004, Journal of affective disorders.

[66]  S. Yamawaki,et al.  Plasma concentrations of interleukin-1beta, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor alpha of depressed patients in Japan. , 2001, Neuropsychobiology.

[67]  S. Rivest,et al.  Interleukin-6 is a needed proinflammatory cytokine in the prolonged neural activity and transcriptional activation of corticotropin-releasing factor during endotoxemia. , 1999, Endocrinology.

[68]  R. Dantzer,et al.  Cytokines and depression: fortuitous or causative association? , 1999, Molecular Psychiatry.

[69]  M. Maes,et al.  Major depression and activation of the inflammatory response system. , 1999, Advances in experimental medicine and biology.

[70]  R. Dantzer,et al.  Cytokines, stress, and depression. Conclusions and perspectives. , 1999, Advances in experimental medicine and biology.

[71]  E. Bosmans,et al.  Plasma soluble interleukin-2-receptor in depression: relationships to plasma neopterin and serum IL-2 concentrations and HPA-axis activity , 1995, European Psychiatry.

[72]  H. Meltzer,et al.  Haptoglobin phenotypes and gene frequencies in unipolar major depression. , 1994, The American journal of psychiatry.

[73]  M. Jadoul,et al.  Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood: II. Application to rheumatoid arthritis and osteoarthritis. , 1992, Cytokine.

[74]  Haimin Xu,et al.  Increase of plasma IL-6 concentration with age in healthy subjects. , 1992, Life sciences.

[75]  E. Bosmans,et al.  Immune disturbances during major depression: upregulated expression of interleukin-2 receptors. , 1990, Neuropsychobiology.

[76]  J. Fleiss.  Measuring nominal scale agreement among many raters. , 1971 .